Pathophysiological regulation of lung function by the free fatty acid receptor FFA4
Rudi Prihandoko, Davinder Kaur, Coen Wiegman, Elisa Alvarez‐Curto, Chantal Donovan, Latifa Chachi, Trond Ulven, Martha R. Tyas, Eloise Euston, Zhaoyang Dong, Abdulrahman Ghali M. Alharbi, Richard Kim, Jack G. Lowe, Philip M. Hansbro, Kian Fan Chung, Christopher E. Brightling, Graeme Milligan, Andrew B. Tobin
Abstract
prostanoid receptors. In normal mice, activation of FFA4 resulted in a decrease in lung resistance. In acute and chronic ozone models of pollution-mediated inflammation and house dust mite and cigarette smoke-induced inflammatory disease, FFA4 agonists acted to reduce airway resistance, a response that was absent in mice lacking expression of FFA4. The expression profile of FFA4 in human lung was similar to that observed in mice, and the response to FFA4/FFA1 agonists similarly mediated human airway smooth muscle relaxation ex vivo. Our study provides evidence that pharmacological targeting of lung FFA4, and possibly combined activation of FFA4 and FFA1, has in vivo efficacy and might have therapeutic value in the treatment of bronchoconstriction associated with inflammatory airway diseases such as asthma and COPD.